{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:17:04Z","timestamp":1773033424253,"version":"3.50.1"},"reference-count":5,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>\n                    This news section offers\n                    <jats:italic>Cancer<\/jats:italic>\n                    readers timely information on events, public policy analysis, and topical issues. In this issue, the FDA recently approved two menin inhibitors for the treatment of relapsed or refractory acute myeloid leukemia with\n                    <jats:italic>NPM1<\/jats:italic>\n                    mutations: revumenib and ziftomenib. In addition, the FDA also approved the subcutaneous injection of anti\u2010CD38 monoclonal antibody daratumumab and hyaluronidase\u2010fihj for patients with high\u2010risk smoldering multiple myeloma, and oral TKI sevabertinib is approved for advanced\n                    <jats:italic>HER2<\/jats:italic>\n                    \u2010mutant NSCLC.\n                  <\/jats:p>","DOI":"10.1002\/cncr.70275","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:14:08Z","timestamp":1772968448000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two new options for\n                    <i>NPM1<\/i>\n                    \u2010mutated relapsed, refractory acute myeloid leukemia"],"prefix":"10.1002","volume":"132","author":[{"given":"Leah","family":"Lawrence","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"e_1_2_2_2_1","unstructured":"FDA approves revumenib for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation. US Food and Drug Administration.October 24 2025. Accessed December 19 2025.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010revumenib\u2010relapsed\u2010or\u2010refractory\u2010acute\u2010myeloid\u2010leukemia\u2010susceptible\u2010npm1\u2010mutation"},{"key":"e_1_2_2_3_1","unstructured":"FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation. US Food and Drug Administration.November 13 2025. Accessed December 19 2025.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010ziftomenib\u2010relapsed\u2010or\u2010refractory\u2010acute\u2010myeloid\u2010leukemia\u2010npm1\u2010mutation"},{"key":"e_1_2_2_4_1","unstructured":"FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. US Food and Drug Administration.November 15 2024. Accessed December 19 2025.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010revumenib\u2010relapsed\u2010or\u2010refractory\u2010acute\u2010leukemia\u2010kmt2a\u2010translocation"},{"key":"e_1_2_2_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.0082"},{"key":"e_1_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6506"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70275","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70275","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T04:28:17Z","timestamp":1773030497000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70275"}},"subtitle":["Researchers are looking into whether revumenib or ziftomenib can be combined with first\u2010line standard\u2010of\u2010care treatment options."],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.1002\/cncr.70275"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70275","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"2026-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70275"}}